Clinical Research Directory

Inclusion Criteria: * 18-75 years * Pathologically diagnosed as stage II or III gastric adenocarcinoma (including gastroesophageal junction). * Receiving radical surgery (R0, D2 resection, more than 16 lymph nodes should be detected) for gastric adenocarcinoma within 2 months prior to enrollment, and not receiving adjuvant treatment. * Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2. * Patients are volunteers, have signed informed consent, and agree to cooperate with investigators in data collection. Exclusion Criteria: * Patients had received neoadjuvant therapy. * Patients who have received or plan to receive targeted therapy and/or immunotherapy。 * Patients allergic to the components of Huaier granules, or avoid to use Huaier granules or use with caution. * More than two active primary tumors at the same time. * Patients have not recovered from surgical complications after radical surgery. * Patients received other Chinese patent medicine with anti-tumor effects.(including but not limited to Huaier Granule, Fufangbanmao Capsule, Huachansu Capsule, Kangai Injection, Pingxiao Table) in the past 1 month. * Not able to take medication orally cause by difficulty in swallowing, complete or incomplete gastrointestinal obstruction, active bleeding from the gastrointestinal tract, perforation, etc. * Pregnant or lactating women or women prepare for pregnancy. * Serious concomitant infection disease. * Patients with severe psychiatric illness or otherwise diseases are unsuitable for this study according to the judgment by investigators. * Patients with combined immune disease and receiving immunosuppressive therapy.